Δ⁹-Tetrahydrocannabinol solution

Papers

The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. Didier M Lambert et al J. Med. Chem. 48, 5059-87, (2005)

---

1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles. John W Huffman et al Bioorg. Med. Chem. Lett. 15, 4110-3, (2005)

---

Sensing with TRP channels. Thomas Voets et al Nat. Chem. Biol. 1, 85-92, (2005)

---

3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data. Outi M H Salo et al J. Med. Chem. 49, 554-66, (2006)

---

The role of fluorine substitution in the structure-activity relationships (SAR) of classical cannabinoids. Peter J Crocker et al Bioorg. Med. Chem. Lett. 17, 1504-7, (2007)

---

2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: orally bioavailable compounds. Hiroyuki Kai et al Bioorg. Med. Chem. Lett. 17, 3925-9, (2007)

---

Hologram QSAR model for the prediction of human oral bioavailability. Tiago L Moda et al Bioorg. Med. Chem. 15, 7738-45, (2007)

---

Novel benzimidazole derivatives as selective CB2 agonists. Daniel Pagé et al Bioorg. Med. Chem. Lett. 18, 3695-700, (2008)

---

Synthesis and pharmacology of 1-deoxy analogs of CP-47,497 and CP-55,940. John W Huffman et al Bioorg. Med. Chem. 16, 322-35, (2008)

---

Antibacterial cannabinoids from Cannabis sativa: a structure-activity study. Giovanni Appendino et al J. Nat. Prod. 71, 1427-30, (2008)

---

Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. R Scott Obach et al Drug Metab. Dispos. 36, 1385-405, (2008)

---

Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents. Pier Giovanni Baraldi et al J. Med. Chem. 53, 5085-107, (2010)

---

Synthesis and structure-activity relationship of substitutions at the C-1 position of Delta9-tetrahydrocannabinol. David Burdick et al Bioorg. Med. Chem. Lett. 20, 1424-6, (2010)

---

Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate. Yun W Alelyunas et al Bioorg. Med. Chem. Lett. 20, 7312-6, (2010)

---

Synthesis and pharmacology of 1-methoxy analogs of CP-47,497. John W Huffman et al Bioorg. Med. Chem. 18, 5475-82, (2010)

---

1-Bromo-3-(1',1'-dimethylalkyl)-1-deoxy-?(8)-tetrahydrocannabinols: New selective ligands for the cannabinoid CB(2) receptor. John W Huffman et al Bioorg. Med. Chem. 18, 7809-15, (2010)

---

Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Denis Fourches et al Chem. Res. Toxicol. 23, 171-83, (2010)

---

Cannabinomimetic lipid from a marine cyanobacterium. Marcelino Gutiérrez et al J. Nat. Prod. 74, 2313-7, (2011)

---

Translating Clinical Findings into Knowledge in Drug Safety Evaluation - Drug Induced Liver Injury Prediction System (DILIps). Zhichao Liu et al PLoS Comput. Biol. 7, e1002310, (2011)

---

?-Carbolines: A novel class of cannabinoid agonists with high aqueous solubility and restricted CNS penetration. Yun-Xing Cheng et al Bioorg. Med. Chem. Lett. 22, 1619-24, (2012)

---

Effects of Δ⁹-THC on VIP-induced prolactin secretion in anterior pituitary cultures: evidence for the presence of functional cannabinoid CB1 receptors in pituitary cells. Rodriguez de Fonseca, F., et al. Brain Res. 841, 114-122, (1999)

---

Cannabinoid modulation of dynorphin A: correlation to cannabinoid-induced antinociception. Mason, D.J. Jr, et al. Eur. J. Pharmacol. 378, 237-248, (1999)

---

Dependence of mesolimbic dopamine transmission on Δ⁹-tetrahydrocannabinol. Tanda, G., et al. Eur. J. Pharmacol. 376, 23-36, (1999)

---

Merck 14,9209